Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics' PST-611 treatmen

Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics' PST-611 treatmen

Results to be presented at ARVO 2026 Annual Meeting- PARIS, April 23, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, will be presenting the results of its PST-611 phase I clinical trial at the ARVO 2026 Annual Meeting May 3-7 in Denver, Colorado. With the follow up of the last patient treated complet…

PulseSight Therapeutics to Present First-in-Human PST-611 Trial Results at ARVO

PulseSight Therapeutics announced it will present results from its phase 1 clinical trial of PST-611 at the Association for Research in Vision and Ophthalmology (ARVO) 2026 annual meeting, taking place May 3–7 in Denver, Colorado. The presentation will mark the first public disclosure of data from the PST-611-CT1 study, a first-in-human trial evaluating the safety and tolerability of the company’s novel non-viral, vectorized gene therapy for the…